Li J Z, Rekhi G S, Augsburger L L, Shangraw R F
University of Maryland at Baltimore, Department of Pharmaceutical Sciences, School of Pharmacy 21201-1180, USA.
Pharm Dev Technol. 1996 Dec;1(4):343-55. doi: 10.3109/10837459609031429.
The objective of this study was to examine the influence of intra- and extragranular microcrystalline cellulose (MCC) on drug dissolution from tablets made by high-shear granulation. Granulations were made in a Littleford Model W-10-B (10-liter) mixer and dried in a fluid bed dryer (Niro Inc.). A Plackett-Burman screening design and 2(3) factorial design were employed to study how drug type, MCC (intra- or extra-), filler type (lactose or dicalcium phosphate), disintegrant type (sodium starch glycolate or croscarmellose sodium) and level, proportion of magnesium stearate, and impeller speed affect tablet hardness, disintegration time, and dissolution. Two model drugs were chosen based on their solubility: metoprolol tartrate (solubility > 1000 mg/ml) and hydrochlorothiazide (solubility = 1.05 mg/ml). Tablets were compressed to the same target weight (dose) and similar tablet hardness. In some cases, dissolution testing was also carried out on the loose granules. The intra-extragranular distribution of MCC was found critical to the compactibility and initial dissolution rates from these tablets. Intragranular MCC reduced drug dissolution, the effect being most marked in the case of the slightly soluble hydrochlorothiazide. For formulations containing intragranular MCC, the granulating fluid level on tablet dissolution was also important, since an increase in fluid level resulted in slower drug dissolution from both the loose granules and the tablets compressed from them. Conversely, extragranular MCC tended to increase both dissolution rates and compactibility. It may be concluded that the appropriate distribution of MCC between and within granules may optimize both dissolution and compactibility without changing overall tablet composition.
本研究的目的是考察颗粒内和颗粒外微晶纤维素(MCC)对高剪切制粒法制得片剂中药物溶出的影响。制粒在Littleford型号W - 10 - B(10升)混合机中进行,并在流化床干燥器(Niro公司)中干燥。采用Plackett - Burman筛选设计和2(3)析因设计来研究药物类型、MCC(颗粒内或颗粒外)、填充剂类型(乳糖或磷酸氢钙)、崩解剂类型(淀粉乙醇酸钠或交联羧甲基纤维素钠)及其用量、硬脂酸镁比例和搅拌桨速度如何影响片剂硬度、崩解时间和溶出度。基于溶解度选择了两种模型药物:酒石酸美托洛尔(溶解度>1000 mg/ml)和氢氯噻嗪(溶解度 = 1.05 mg/ml)。将片剂压制成相同的目标重量(剂量)和相似的片剂硬度。在某些情况下,还对松散颗粒进行了溶出度测试。发现MCC的颗粒内 - 外分布对这些片剂的可压性和初始溶出速率至关重要。颗粒内MCC降低了药物溶出,这种影响在微溶性氢氯噻嗪的情况下最为明显。对于含有颗粒内MCC的制剂,制粒液水平对片剂溶出也很重要,因为液位升高会导致松散颗粒及其压制片剂的药物溶出变慢。相反,颗粒外MCC倾向于提高溶出速率和可压性。可以得出结论,在颗粒之间和颗粒内部适当分布MCC可以在不改变片剂整体组成的情况下优化溶出度和可压性。